ImmunoVec

Recent Finacing

Grant

Recent Raise

$40.7M

ImmunoVec is a biotechnology company developing an in vivo cell-engineering platform that uses DNA-loaded polymeric nanoparticles to reprogram immune cells for treating autoimmune diseases and other serious conditions.

California, United States

1-10

Private

immunovec.com

Highlights

Focus Areas

Biotechnology

Genetics

Health Care

Medical

Recent Investors

Financials

$40.7M

Total Raised

1

Funding round

1

Investor

Team

Upgrade to view the team

See the team members at ImmunoVec.